spacer
home > pmps > winter 2019 > contamination control
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Contamination Control

Pharmaceutical companies may unwittingly be putting production processes at risk of contamination by fitting mechanical seals made from unsafe materials. Seals which fail to comply with industry regulations might slip through the net, and the solution to avoiding the contamination risk could actually be very simple.

Mechanical seals have a key function in pharma production processes. However, because they are regarded as component parts, they are often overlooked when it comes to compliance with FDA regulations and pharma current Good Manufacturing Practice (cGMP).

Crossover between the pharma, biopharmaceutical, and food and beverage sectors is routine the use of the dairy by-product β-lactose as an excipient is a typical example. Therefore, it makes sense that both cGMP and the regulations governing food contact materials (FCMs) must apply equal weight in both sectors.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
John Smiddy is the European Regional Business Development and Technical Support Director for AESSEAL. Since joining the company in 1995, he has worked in many chemical and pharma plants, solving complex sealing problems and offering solutions to extend mechanical seal life. John has extensive knowledge of the chemical, pharma, and food and beverage industries and of the regulation around pharma production. He is a leader within AESSEAL, promoting mechanical seal standards for this sector.
spacer
John Smiddy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement